Jade Biosciences (JBIO) risk factors
Item 1A of every Jade Biosciences, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
72 risks, 64 new, 54 dropped, 8 reworded since the prior year. Company is a clinical-stage biotechnology firm reliant on lead program JADE101 and external capital raising. Risk disclosures reflect transition to public company status, clinical trial execution, and intellectual property protection.
Filed Mar 06, 2026 - FY2024 10-K risk factors
62 risks. Jade Biosciences has a limited operating history and incurred cumulative operating losses of $233.1 million through December 31, 2024. The company halted the Phase 3 clinical trial of its sole product candidate AV-101 for pulmonary arterial hypertension in June 2024. Operations are heavily focused on completing a pending merger with Jade and executing a $300.0 million pre-closing financing.
Filed Mar 27, 2025